Compare INFY & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFY | A |
|---|---|---|
| Founded | 1981 | 1999 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5B | 39.8B |
| IPO Year | 1999 | 1999 |
| Metric | INFY | A |
|---|---|---|
| Price | $12.69 | $135.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $14.60 | ★ $161.47 |
| AVG Volume (30 Days) | ★ 14.6M | 2.2M |
| Earning Date | 04-23-2026 | 05-27-2026 |
| Dividend Yield | ★ 3.56% | 0.92% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | N/A | ★ $4,472,000,000.00 |
| Revenue This Year | $2.87 | $8.45 |
| Revenue Next Year | $6.67 | $6.13 |
| P/E Ratio | ★ $19.11 | $127.07 |
| Revenue Growth | N/A | ★ 6.43 |
| 52 Week Low | $11.56 | $108.35 |
| 52 Week High | $30.00 | $160.27 |
| Indicator | INFY | A |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 76.61 |
| Support Level | $12.65 | $121.63 |
| Resistance Level | $13.04 | $137.85 |
| Average True Range (ATR) | 0.44 | 3.63 |
| MACD | 0.09 | 2.39 |
| Stochastic Oscillator | 67.06 | 87.55 |
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.